# A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PTT-621 in Patients With Moderately to Severely Active Ulcerative Colitis

> **NCT07747155** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Pyrotech Therapeutics, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** PTT-621 Tablets

## Key facts

- **NCT ID:** NCT07747155
- **Lead sponsor:** Pyrotech Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07747155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07747155, "A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PTT-621 in Patients With Moderately to Severely Active Ulcerative Colitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07747155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*